These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 28975300)

  • 1. Characteristics of Novel Therapeutics and Postmarket Safety Events.
    Tanimoto T; Mori J; Oshima Y
    JAMA; 2017 Sep; 318(11):1067. PubMed ID: 28975300
    [No Abstract]   [Full Text] [Related]  

  • 2. Characteristics of Novel Therapeutics and Postmarket Safety Events-Reply.
    Downing NS; Shah ND; Ross JS
    JAMA; 2017 Sep; 318(11):1067-1068. PubMed ID: 28975302
    [No Abstract]   [Full Text] [Related]  

  • 3. Postmarket surveillance. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jun; 67(109):38878-92. PubMed ID: 12053947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [United States Medical Device Postmarket Surveillance System Operational Experience and Learning].
    Zhu S; Xu X
    Zhongguo Yi Liao Qi Xie Za Zhi; 2017 Mar; 41(2):123-126. PubMed ID: 29862685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Data, Advanced Analytics, and the Evolution of Postmarket Drug Safety Surveillance.
    Dal Pan GJ
    Clin Pharmacol Ther; 2019 Jul; 106(1):28-30. PubMed ID: 30958565
    [No Abstract]   [Full Text] [Related]  

  • 6. IOM outlines framework for postmarket safety.
    Reinke T
    Manag Care; 2012 Aug; 21(8):10-1. PubMed ID: 22957462
    [No Abstract]   [Full Text] [Related]  

  • 7. Medical device safety: FDA's postmarket transformation initiative.
    Schultz D
    Food Drug Law J; 2007; 62(3):593-6. PubMed ID: 17915401
    [No Abstract]   [Full Text] [Related]  

  • 8. Keeping an Eye On Medical Devices Postmarket Surveillance Enters New Age.
    Vockley M
    Biomed Instrum Technol; 2015; 49(6):378-82, 389. PubMed ID: 26618832
    [No Abstract]   [Full Text] [Related]  

  • 9. IOM advises FDA on ethics in postmarket safety trials.
    Kuehn BM
    JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
    [No Abstract]   [Full Text] [Related]  

  • 10. CDRH's postmarket surveillance proposal.
    Health Devices; 2012 Dec; 41(12):400. PubMed ID: 23444687
    [No Abstract]   [Full Text] [Related]  

  • 11. Postmarket surveillance for medical devices: America's new strategy.
    Normand SL; Hatfield L; Drozda J; Resnic FS
    BMJ; 2012 Oct; 345():e6848. PubMed ID: 23060660
    [No Abstract]   [Full Text] [Related]  

  • 12. Postmarket medical device safety: moving beyond voluntary reporting.
    Resnic FS; Majithia A
    BMJ Qual Saf; 2018 Mar; 27(3):174-175. PubMed ID: 28993440
    [No Abstract]   [Full Text] [Related]  

  • 13. Back to Reality: The Postmarket Surveillance System Today.
    Biomed Instrum Technol; 2015; 49(6):384-9. PubMed ID: 26618844
    [No Abstract]   [Full Text] [Related]  

  • 14. Hear no evil, see no evil, speak no evil: postmarket monitoring, underreporting, and estimating the prevalence of endograft-related adverse events.
    Chaikof EL
    J Vasc Surg; 2002 Jun; 35(6):1299-300. PubMed ID: 12042748
    [No Abstract]   [Full Text] [Related]  

  • 15. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advocates call for FDA to take tougher stance on postmarket safety studies.
    Kuehn BM
    JAMA; 2011 Oct; 306(15):1639-40, 1642. PubMed ID: 22009087
    [No Abstract]   [Full Text] [Related]  

  • 17. Postmarket Surveillance of Blood Glucose Monitor Systems Is Needed for Safety of Subjects and Accurate Determination of Effectiveness in Clinical Trials of Diabetes Drugs and Devices.
    Klonoff DC
    J Diabetes Sci Technol; 2019 May; 13(3):419-423. PubMed ID: 30974987
    [No Abstract]   [Full Text] [Related]  

  • 18. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
    Samuel AM; Rathi VK; Grauer JN; Ross JS
    Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the Power of Collaboration for Postmarket Surveillance of Hernia Mesh Devices.
    Prabhu AS; Poulose BK; Rosen MJ
    Ann Surg; 2020 Feb; 271(2):221-222. PubMed ID: 31290762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.